Valvular Heart Disease Treatment Market Competitive Analysis 2019 to 2027

Posted by Rohini Chaudhari on June 21st, 2019

Valvular Heart Disease Treatment Market Introduction

Pulmonic, aortic, mitral, and tricuspid are the four types of heart valves, which control the flow of blood across the heart chambers and their connecting arteries. Damage to any of the valves can lead to valvular diseases. Valvular diseases are treated by repairing or replacing the heart valves. Fatigue, swelling of feet or ankles, dizziness, abnormal sound, and irregular heartbeat are the symptoms of valvular heart disease. Valvular heart diseases can also be caused due to infection or other heart conditions. Congenital heart disease, heart failure, high blood pressure, and old age are the risk factors for valvular heart disease.

Report Overview @ https://www.transparencymarketresearch.com/valvular-heart-disease-treatment-market.html

Valvular Heart Disease Treatment Market – Competition Landscape

The global valvular heart disease treatment market is highly consolidated with presence of few players holding major share of the market. Key players are engaged in the development of new products and technologies, extension of device indications, and product approvals. Leading players operating in the global valvular heart disease treatment market are Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, Neovasc, Inc., Medtronic, Abbott, LifeNet Health, LivaNova plc, Micro Interventional Devices, Inc., Edwards Lifesciences Corporation, and CryoLife, Inc.

Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=68105

Boston Scientific Corporation:

Founded in 1960, the US based Boston Scientific Corporation is one of the key players operating in global valvular heart disease market, offering products under its cardiovascular business segment. It has a strong pipeline of innovative valvular heart disease treatment products. In April 2019, Boston Scientific Corporation received approval from the U.S. Food and Drug Administration for LOTUS Edge Aortic valve system for minimally invasive procedure.